|
US2013150282A1
|
|
Ltbp2 as a biomarker for evaluating the risk of death in a diseased subject
|
|
CA2859295A1
|
|
Biomarkers and parameters for preeclampsia
|
|
WO2013083781A2
|
|
Biomarkers and test panels useful in systemic inflammatory conditions
|
|
CA2858455A1
|
|
Ltbp2 as a biomarker for lung injury
|
|
EP2766734A1
|
|
Procathepsin l and cathepsin l as biomarkers for ischemia
|
|
WO2013023994A1
|
|
New biomarker for the classification of ovarian tumours
|
|
WO2012156447A1
|
|
New biomarker for the classification of ovarian tumours
|
|
AU2011275753A1
|
|
Quiescin Q6 as biomarker for hypertensive disorders of pregnancy
|
|
EP2514831A1
|
|
New biomarker for measuring beta cell activity
|
|
US2011251094A1
|
|
Biomarkers for hypertensive disorders of pregnancy
|
|
EP2558868A2
|
|
Biomarkers for hypertensive disorders of pregnancy
|
|
CA2788760A1
|
|
Ltbp2 as a biomarker for renal dysfunction
|
|
WO2010086382A1
|
|
Target for treatment of acute heart failure
|
|
WO2010086386A1
|
|
Protein quantification methods and use thereof for candidate biomarker validation
|
|
WO2010086384A1
|
|
Target for treatment of acute heart failure
|
|
CA2746128A1
|
|
Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof
|
|
WO2009141359A1
|
|
New biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof
|
|
US2011256169A1
|
|
Novel polypeptides related to b-type natriuretic peptides and methods of their identification and use
|
|
CN101835904A
|
|
Method of selecting aptamers
|
|
US2010311114A1
|
|
Preparation of samples for proteome analysis
|
